DBVT (DBV Technologies) Price-to-Operating-Cash-Flow : (As of May. 12, 2025)

View and export this data going back to 2014. Start your Free Trial

What is DBV Technologies Price-to-Operating-Cash-Flow?

As of today (2025-05-12), DBV Technologies's share price is $10.655. DBV Technologies's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-4.56. Hence, DBV Technologies's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for DBV Technologies's Price-to-Operating-Cash-Flow or its related term are showing as below:

DBVT's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 23.675
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

DBV Technologies's Cash Flow from Operations per share for the three months ended in Mar. 2025 was $-0.96. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-4.56.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 16.10% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 26.50% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 8.20% per year.

During the past 13 years, DBV Technologies's highest 3-Year average Operating Cash Flow per Share Growth Rate was 42.70% per year. The lowest was -56.10% per year. And the median was -13.50% per year.

DBV Technologies Price-to-Operating-Cash-Flow Historical Data

The historical data trend for DBV Technologies's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DBV Technologies Price-to-Operating-Cash-Flow Chart

DBV Technologies Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

DBV Technologies Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of DBV Technologies's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, DBV Technologies's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DBV Technologies's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DBV Technologies's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where DBV Technologies's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

DBV Technologies Price-to-Operating-Cash-Flow Calculation

DBV Technologies's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	10.655	/	-4.564
	=

DBV Technologies's Share Price of today is $10.655.
DBV Technologies's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.56.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

DBV Technologies Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of DBV Technologies's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

DBV Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DBV Technologies SA (NAS:DBVT) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

0QAJ:UK DBV:France DBV:Germany DBV:Germany

Address

107 Avenue de la Republique, Batiment IRO, Chatillon, Paris, FRA, 92320

Website

https://www.dbv-technologies.com

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Executives

Pharis Mohideen	officer: Chief Medical Officer	C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451
Daniel Tasse	director, officer: Chief Executive Officer	C/O IKARIA, INC., 6 STATE ROUTE 173, CLINTON NJ 08809
Adora Ndu	director	C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Virginie Boucinha	officer: Chief Financial Officer	C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Timothy E Morris	director	ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Daniel B Soland	director	4560 HORTON STREET,M/S R-422, EMERYVILLE CA 94608
Daniele Guyot-caparros	director	C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Julian Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Felix Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Madduri Ravin Rao	director	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, #250, AUSTIN TX 78746
Michael Goller	director	C/O BAKER BROTHERS INVESTMENTS, 667 MADISON AVENUE, 21ST FLOOR, NEW YORK NY 10065
Rosen Michel De	director	C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341